| Primary |
| Drug Use For Unknown Indication |
25.4% |
| Herpes Zoster |
21.5% |
| Product Used For Unknown Indication |
14.8% |
| Encephalitis Herpes |
5.4% |
| Hypertension |
3.7% |
| Oral Herpes |
3.1% |
| Prophylaxis |
2.9% |
| Genital Herpes |
2.7% |
| Herpes Simplex |
2.6% |
| Pain |
2.6% |
| Herpes Virus Infection |
2.3% |
| Varicella |
2.3% |
| Herpes Ophthalmic |
2.1% |
| Infection |
1.8% |
| Insomnia |
1.4% |
| Encephalitis |
1.3% |
| Pyrexia |
1.2% |
| Convulsion |
1.0% |
| Ocular Hypertension |
1.0% |
| Diabetes Mellitus |
0.9% |
|
| Renal Failure Acute |
17.8% |
| Vomiting |
10.5% |
| Drug Ineffective |
8.8% |
| Product Quality Issue |
7.9% |
| Pharmaceutical Product Complaint |
7.7% |
| Tremor |
4.5% |
| Toxic Epidermal Necrolysis |
4.3% |
| Somnolence |
4.1% |
| Pyrexia |
3.9% |
| Encephalopathy |
3.4% |
| Renal Impairment |
3.4% |
| Speech Disorder |
3.4% |
| Rash |
3.2% |
| Nervous System Disorder |
3.0% |
| Restlessness |
3.0% |
| Renal Failure |
2.6% |
| Hallucination |
2.4% |
| Depressed Level Of Consciousness |
2.1% |
| Urinary Retention |
2.1% |
| Nausea |
1.9% |
|
| Secondary |
| Hypertension |
15.0% |
| Ocular Hypertension |
13.5% |
| Adult T-cell Lymphoma/leukaemia |
13.2% |
| Herpes Zoster |
10.8% |
| Drug Use For Unknown Indication |
7.1% |
| Product Used For Unknown Indication |
7.0% |
| Prophylaxis |
5.6% |
| Constipation |
3.4% |
| Pyrexia |
3.1% |
| Antifungal Prophylaxis |
2.3% |
| Infection Prophylaxis |
2.3% |
| Renal Transplant |
2.2% |
| Rheumatoid Arthritis |
2.1% |
| Pain |
2.0% |
| Pneumonia |
2.0% |
| Genital Herpes |
2.0% |
| Somnolence |
1.8% |
| Encephalitis Herpes |
1.5% |
| Asthma |
1.5% |
| Insomnia |
1.3% |
|
| Visual Acuity Reduced |
18.6% |
| Renal Failure Acute |
10.3% |
| Vomiting |
9.6% |
| Cataract |
6.5% |
| Stevens-johnson Syndrome |
6.5% |
| Interstitial Lung Disease |
4.5% |
| Renal Impairment |
4.1% |
| Toxic Epidermal Necrolysis |
4.1% |
| Restlessness |
3.8% |
| Drug Ineffective |
3.4% |
| Renal Failure |
3.4% |
| Thrombocytopenia |
3.4% |
| Toxic Induced Encephalopathy |
3.4% |
| Personality Change |
3.1% |
| Aggression |
2.7% |
| Renal Disorder |
2.7% |
| Graft Versus Host Disease |
2.4% |
| Pyrexia |
2.4% |
| Skin Exfoliation |
2.4% |
| Speech Disorder |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
19.2% |
| Drug Use For Unknown Indication |
19.2% |
| Prophylaxis |
14.3% |
| Multiple Myeloma |
6.5% |
| Infection Prophylaxis |
6.0% |
| Diffuse Large B-cell Lymphoma |
4.5% |
| Stem Cell Transplant |
3.7% |
| Immunosuppression |
3.2% |
| Hypertension |
3.1% |
| Hiv Infection |
3.0% |
| Prophylaxis Against Graft Versus Host Disease |
2.7% |
| Pain |
2.4% |
| Herpes Zoster |
2.2% |
| Allogenic Bone Marrow Transplantation Therapy |
2.1% |
| Acute Myeloid Leukaemia |
1.9% |
| Renal Transplant |
1.2% |
| Rheumatoid Arthritis |
1.2% |
| Graft Versus Host Disease |
1.2% |
| Osteoporosis |
1.2% |
| Constipation |
1.2% |
|
| Vomiting |
13.0% |
| Pyrexia |
9.0% |
| White Blood Cell Count Decreased |
7.6% |
| Sepsis |
7.3% |
| Febrile Neutropenia |
7.0% |
| Pneumonia |
6.3% |
| Weight Decreased |
4.9% |
| Weight Increased |
4.3% |
| Respiratory Failure |
4.0% |
| Pulmonary Embolism |
3.9% |
| Wheezing |
3.8% |
| Toxic Epidermal Necrolysis |
3.7% |
| Thrombocytopenia |
3.5% |
| Venoocclusive Liver Disease |
3.5% |
| Nausea |
3.2% |
| Septic Shock |
3.2% |
| Hepatic Function Abnormal |
3.0% |
| Renal Impairment |
2.9% |
| Stomatitis |
2.9% |
| Thrombotic Microangiopathy |
2.9% |
|
| Interacting |
| Disseminated Tuberculosis |
20.0% |
| Contraception |
16.7% |
| Oral Herpes |
16.7% |
| Product Used For Unknown Indication |
16.7% |
| Combined Immunodeficiency |
13.3% |
| Pain |
6.7% |
| Crohn's Disease |
3.3% |
| Encephalitis |
3.3% |
| Herpes Zoster |
3.3% |
|
| Dysfunctional Uterine Bleeding |
55.6% |
| Nausea |
11.1% |
| Neuropathy Peripheral |
11.1% |
| Renal Failure Acute |
11.1% |
| Vomiting |
11.1% |
|
